| | | | | A biotech stock is surging after slashing its annual losses by 63%, a pharma major is tanking upon posting a significant loss, and an IoT system integrator is soaring 35% after signing an MoU for setting up data centers in Malaysia. Read on to find out more. | |
|
| Technology (Sponsored) | | | If you missed out on Apple, Tesla, or Amazon in their early days, you know how painful it is to watch those stocks skyrocket without you. | But here’s the good news—history is about to repeat itself. | We’ve identified 7 rapidly growing companies with the potential to become the next big market winners. These firms are innovating, expanding, and still flying under Wall Street’s radar—but not for long. | Get your FREE report: “The Next Magnificent 7 Stocks for 2025” right here. | Just like the original Magnificent Seven—Apple, Microsoft, Amazon, Alphabet, Nvidia, Meta, and Tesla—these companies are positioned for explosive growth. The key is getting in before the crowd. | Opportunities like this don’t last. Once the mainstream catches on, the biggest gains will be gone. | Click here to claim your free report and discover the next market leaders. | (By clicking the link above, you will get this free report and a free subscription to MarketBeat's daily email newsletter. You are also agreeing to the terms of our privacy policy. Unsubscribe at any time.) |
|
| | | | What to Watch | Earnings: | None Scheduled | Economic Reports: | Personal income and spending [Jan]: 8:30 a.m. PCE index [Jan]: 8:30 a.m. Advanced U.S. trade balance in goods [Jan]: 8:30 a.m. Advanced retail and wholesale inventories [Jan]: 8:30 a.m. Richmond Fed President Tom Barkin will speak at 8:30 a.m. Chicago Business Barometer (PMI) [Feb]: 9:45 a.m. Chicago Fed President Austan Goolsbee will speak at 10:15 p.m. |
|
| | Biopharma | Apellis Stock Surging on Strong Revenue Growth, Possible Profitability Path | | Apellis Pharmaceuticals [NASDAQ: APLS] reported strong financial performance for 2024, with total revenue reaching $781.4 million, marking a 97% increase from the previous year. | The company’s flagship drug, SYFOVRE®, generated $611.9 million in sales, while EMPAVELI® contributed $98.1 million. | Apellis significantly narrowed its net loss to $197.9 million, a 63% reduction from the $528.6 million loss recorded in 2023. | This improvement, coupled with a strong cash position of $411.3 million as of December 31, 2024, has fueled optimism about Apellis reaching profitability, sending its stock up by more than 11% in premarket trade today. | Another key development is the company’s submission of a supplemental new drug application for EMPAVELI to treat C3G and IC-MPGN, with an anticipated U.S. launch in the second half of 2025. | In the fourth quarter alone, Apellis delivered approximately 94,000 SYFOVRE doses, with over 510,000 injections administered since the drug’s launch. | With rising product revenue and a strategic growth plan, Apellis appears to be positioning itself for sustained success and potential profitability in the near future. |
|
| | Pharmaceuticals | Recursion Pharmaceuticals Stock Plunging as Institutional Investors Weigh Options | | Recursion Pharmaceuticals [NASDAQ: RXRX] shares are plunging 11% in premarket trade, continuing on from an 8% decline yesterday. | The company reported a net loss of $463.7 million for the year and will end 2024 with $603 million in cash reserves, which it expects to support its operations into 2027. | This latest drop adds to a broader one-year decline of 418%, raising concerns among institutional investors who own 75% of the company’s shares. | With 11 major institutional investors holding a combined 51% stake, any large-scale sell-off could trigger further declines, potentially impacting smaller investors as well. | However, the company reported that it remains focused on advancing its clinical pipeline and accelerating AI-driven breakthroughs in drug discovery. | It has shown promising early results for its investigational treatments, including REC-617, an oral CDK7 inhibitor, which showed encouraging safety and efficacy in a Phase 1/2 study. | REC-994, a potential treatment for cerebral cavernous malformations, met key study endpoints and demonstrated signs of symptom stabilization. |
|
| | | | Pharmaceuticals | Amneal Pharmaceuticals Surpasses Revenue Estimates, Shares Gain Over 3% | | Amneal Pharmaceuticals Inc. [NASDAQ: AMRX] shares are climbing more than 1.4% in premarket trading today on stronger-than-expected fourth-quarter revenue and an optimistic outlook for 2025. | The pharmaceutical firm generated $731 million in revenue for the final quarter of 2024, surpassing analyst predictions of $703.74 million. | This marks an 18% increase from the previous year, driven by robust performance across its Affordable Medicines, AvKARE, and Specialty segments. | However, adjusted earnings per share came in at $0.12, falling short of the anticipated $0.15. | Looking ahead, Amneal expects full-year 2025 revenue to range between $3 billion and $3.1 billion, exceeding Wall Street’s projection of $2.92 billion. | The company also forecasts adjusted earnings per share between $0.65 and $0.70, slightly below the $0.71 consensus estimate. | Co-CEOs Chirag and Chintu Patel emphasized the company’s focus on disciplined execution, innovation, and strategic investments as key drivers of its ongoing growth. | Amneal also highlighted the successful launch of CREXONT and noted that it had reduced net leverage to 3.9x—achieving this goal a year earlier than expected. | Despite missing earnings estimates, investors appear to be responding positively to the company’s revenue growth and bullish guidance, pushing shares higher in early trading. |
|
| | Movers and Shakers | | ARB IOT Group Limited [ARBB] - Last Close: $0.48 | ARB IOT Group Limited is a technology company specializing in IoT system integration. | Its stock is up 35% in premarket trade after announcing a Memorandum of Understanding (MOU) to establish an AI data center experimental laboratory in Malaysia, giving it an advantage in capturing growth in Malaysia’s AI and data-driven economy. | My Take: This is a tiny stock with high volatility in the AI space. While the stock has declined nearly 73% in the last year, it might be good to keep your eye on how its Malaysia bet pans out. |
|
|
|
| Elastic N.V. [ESTC] - Last Close: $101.28 | Elastic N.V. is an enterprise data analytics and search platform. | Its shares are up 13% in early trade as the company beat its Q3 revenue estimates and issued strong guidance for fiscal 2025. | The firm reported $382.1M revenue in Q3, surpassing the $369M market estimate. Q4 revenue outlook of $379M–$381M and full-year guidance of $1.474B–$1.476B are also above expectations. | My Take: Elastic has struggled to gain positive net margins in recent quarters but this revenue surge might signal a turnaround. The stock is up 27% in the last six months. Keep it on your radar and watch whether it can hold its positive streak. |
|
|
|
| Organogenesis Holdings Inc. [ORGO] - Last Close: $3.07 | Organogenesis Holdings Inc. is a regenerative medicine company specializing in advanced wound care, surgical, and sports medicine products to improve patient outcomes. | Its shares are climbing in premarket trading after reporting a strong Q4 earnings beat, with net revenue surging 27% year-over-year to $126.7 million. The company also returned to profitability, posting $7.7 million in net income, compared to a $0.6 million loss in Q4 2023. | My Take: Adjusted EBITDA more than doubled to $18.2 million, reflecting strong operational efficiency. Moreover, its upcoming ReNu BLA submission for knee osteoarthritis (OA) could also be a game changer. Keep a close eye on this one. |
|
|
|
| | | | | | That’s all for today. Thank you for reading. If you have any feedback, please reply to this email. | Best Regards, | — Adam Garcia
Elite Trade Club |
|
| | | | | | Click here to get our daily newsletter straight to your cell for free. | P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP. |
| |
|
|
|
